专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

111. 发明申请

US20190282674A1 USE OF HYALURONIDASE FOR TREATMENT OF MUSCLE STIFFNESS 审中-公开
公开(公告)号：US20190282674A1
公开(公告)日：2019-09-19
申请号：US16429272
申请日：2019-06-03
申请人： New York University
发明人： Preeti RAGHAVAN , Antonio STECCO
IPC分类号： A61K38/47 , A61P21/02 , A61K9/00 , A61K47/02
摘要： Provided are methods and kits for reducing the severity of muscle stiffness. The method comprises delivering to one or more specific locations in the deep fascia of an affected muscle a composition comprising a therapeutically effective amount of hyaluronidase.

112. 发明申请

US20190177370A1 PEPTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PRODRUG THEREOF 审中-公开
公开(公告)号：US20190177370A1
公开(公告)日：2019-06-13
申请号：US16324495
申请日：2017-08-08
申请人： TOKYO UNIVERSITY OF PHARMACY & LIFE SCIENCES
发明人： Yoshio HAYASHI , Kentaro TAKAYAMA , Yoichi NEGISHI
IPC分类号： C07K7/08 , A61P21/02 , A61P21/04 , A61K47/66
摘要： Provided is a peptide having a short chain length, for example, having the number of amino acid residues of 20 or less and having a high myostatin inhibitory activity. The present invention is a peptide comprising an amino acid sequence represented by Formula (1) in the specification and having the number of amino acid residues of 20 or less.

113. 发明授权

US10307467B2 Use of hyaluronidase for treatment of muscle stiffness 有权
公开(公告)号：US10307467B2
公开(公告)日：2019-06-04
申请号：US15325938
申请日：2015-07-16
申请人： New York University
发明人： Preeti Raghavan , Antonio Stecco
IPC分类号： A61K38/47 , A61K47/02 , A61K9/00 , A61P21/02
摘要： Provided are methods and kits for reducing the severity of muscle stiffness. The method comprises delivering to one or more specific locations in the deep fascia of an affected muscle a composition comprising a therapeutically effective amount of hyaluronidase.

114. 发明申请

US20190077860A1 ANTI-EPHA4 ANTIBODY 审中-公开
公开(公告)号：US20190077860A1
公开(公告)日：2019-03-14
申请号：US15753611
申请日：2016-09-06
申请人： EISAI R&D MANAGEMENT CO., LTD.
发明人： Ryota Taguchi , Toshio Imai , Eiji Inoue , Akio Yamada , Aki Nakatani , Toshifumi Hirayama , Yuichi Ono , Shunsuke Ito
IPC分类号： C07K16/28 , A61P25/28 , A61P21/02 , C12N15/62
CPC分类号： C07K16/28 , A61K2039/505 , A61P21/02 , A61P25/28 , C07K16/2866 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N15/62
摘要： It is intended to provide an anti-EphA4 antibody or an EphA4-binding fragment thereof which is capable of binding to EphA4 and inhibiting the binding between EphA4 and its ligand, and a pharmaceutical composition comprising the anti-EphA4 antibody or the EphA4-binding fragment thereof as an active ingredient. A mouse anti-EphA4 antibody having binding affinity for EphA4 was obtained, and the sequences of complementarity-determining regions (CDRs) of the mouse anti-EphA4 antibody were identified. This allowed for preparation of a humanized antibody comprising the CDR sequences of the mouse anti-EphA4 antibody in heavy chain variable region and light chain variable region.

115. 发明申请

US20180214482A1 METHOD OF ENABLING MUSCLE RELAXATION 审中-公开
公开(公告)号：US20180214482A1
公开(公告)日：2018-08-02
申请号：US15752343
申请日：2016-08-11
申请人： SENSE TECHNOLOGY, INC.
发明人： Joseph M. Evans
IPC分类号： A61K33/42 , A61K33/14 , A61K33/06 , A61K31/7076 , A61P21/02
CPC分类号： A61K33/42 , A61K31/7076 , A61K33/00 , A61K33/06 , A61K33/14 , A61K2300/00 , A61P21/02
摘要： A method of application to human skin of a water solution of metallic salts at concentrations from 1 to not more than 10 times the normal concentration found in the interstitial cellular space in humans, including the addition of ADP, ATP, to enable muscle relaxation and restore normal muscle function in humans.

116. 发明授权

US09040508B2 Compositions of protein receptor tyrosine kinase inhibitors 有权
标题翻译：蛋白质受体酪氨酸激酶抑制剂的组成
公开(公告)号：US09040508B2
公开(公告)日：2015-05-26
申请号：US13133565
申请日：2009-12-08
申请人： Jay Jie-Qiang Wu , Ling Wang
发明人： Jay Jie-Qiang Wu , Ling Wang
IPC分类号： A61K31/496 , C07D413/02 , C07D413/10 , C07D215/20 , C07D221/06 , C07D223/32 , C07D241/44 , C07D261/20 , C07D265/36 , C07D279/16 , C07D295/13 , C07D307/77 , C07D403/14 , C07D413/12 , C07D417/12 , C07D487/04 , C07D491/04 , C07D493/06 , C07D495/04 , C07D498/04 , C07D498/06 , C07D513/04 , A61K45/06 , A61K31/56 , C07D413/14 , C07D471/04 , C07D207/06 , C07D403/12 , C07D401/12 , A61K31/4985 , A61K31/5415 , A61K31/40 , A61K31/4025 , A61K31/435 , A61K31/404 , A61K31/515 , A61K31/5513 , A61P35/00 , A61P23/00 , A61P25/08 , A61P25/34 , A61P29/00 , A61P9/10 , A61P9/00 , A61P17/06 , A61P21/02 , A61P25/22 , A61P3/10 , A61P31/12 , A61P25/30 , A61P25/32 , A61P35/04
CPC分类号： C07D498/06 , A61K31/496 , A61K31/497 , A61K45/06 , C07D215/20 , C07D221/06 , C07D223/32 , C07D241/44 , C07D261/20 , C07D265/36 , C07D279/16 , C07D295/13 , C07D307/77 , C07D403/14 , C07D407/12 , C07D413/10 , C07D413/12 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D493/06 , C07D495/04 , C07D498/04 , C07D513/04
摘要： The present invention relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same that are capable of inhibiting or antagonizing a family of receptor tyrosine kinases, Tropomysosin Related Kinases (Trk), in particular the nerve growth factor (NGF) receptor, TrkA. The invention further concerns the use of such compounds in the treatment and/or prevention of pain, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, or a disease, disorder or injury relating to dysmyelination or demyelination or the disease or disorder associated with abnormal activities of NGF receptor TrkA.
摘要翻译：本发明涉及新型合成取代的杂环化合物和含有能够抑制或拮抗受体酪氨酸激酶家族（Tropomysosin Related Kinases，Trk），特别是神经生长因子（NGF）受体TrkA的家族的合成取代的杂环化合物和药物组合物。本发明还涉及这些化合物在治疗和/或预防疼痛，癌症，再狭窄，动脉粥样硬化，牛皮癣，血栓形成或与异常髓鞘或脱髓鞘有关的疾病，病症或损伤或与异常活动有关的疾病或病症的NGF受体TrkA。

117. 发明申请

US20130309215A1 PHARMACEUTICAL COMPOSITION 审中-公开
标题翻译：药物组合物
公开(公告)号：US20130309215A1
公开(公告)日：2013-11-21
申请号：US13571799
申请日：2012-08-10
申请人： Bernd G. SEIGFRIED
发明人： Bernd G. SEIGFRIED
IPC分类号： A61K47/44 , A61P37/08 , A61P17/00 , A61P25/00 , A61P31/00 , A61K31/49 , A61P31/10 , A61K31/454 , A61K31/405 , A61K31/557 , A61P29/00 , A61P5/26 , A61P5/28 , A61K31/56 , A61P25/08 , A61P7/02 , A61K38/43 , A61K31/7105 , A61K31/711 , A61K31/713 , A61P17/04 , A61P3/10 , A61P31/12 , A61P37/06 , A61P17/12 , A61P17/02 , A61K36/00 , A61P25/18 , A61P25/20 , A61P21/02 , A61P1/08 , A61P33/00 , A61P1/16 , A61P9/00 , A61P11/10 , A61P31/04 , A61P11/14 , A61P11/06 , A61P7/10 , A61P37/02 , A61K31/196 , A61K31/192 , A61P25/16 , A61P3/02 , A61P23/02
CPC分类号： A61K31/196 , A61K9/0014 , A61K31/192 , A61K36/28 , A61K36/48 , A61K36/899 , A61K38/00 , A61K47/10 , A61K47/24 , A61K47/44 , A61K2300/00
摘要： A pharmaceutical composition for application in human and animals, with at least one systemically and/or locally acting, topically applicable active ingredient and with at least one phospholipid, improving the transport of the active ingredient trough the cell membrane and containing a concentration of at least 60% by weight phosphatidylcholine, referring to the phospholipid, is described. The composition shows such a liquid consistency, that it is able to be sprayed as droplets or as a foam, whereas in the composition such a phospholipid is included, that additionally contains oil in a concentration of maximum 7.5% by weight besides the at least 60% by weight phosphatidylcholine.
摘要翻译：一种用于人和动物的药物组合物，其具有至少一种全身和/或局部作用的局部应用的活性成分和至少一种磷脂，其改善了活性成分在细胞膜的运输并且至少含有至少涉及磷脂的60重量％磷脂酰胆碱被描述。该组合物显示出这样的液体稠度，其能够以小滴或泡沫形式喷雾，而在组合物中包含这样的磷脂，除了至少60重量份之外，还含有浓度最大为7.5重量％的油重量百分比的磷脂酰胆碱。

118. 发明申请

US20130189344A1 HUMAN LUBRICATION GEL 有权
标题翻译：人体润滑凝胶
公开(公告)号：US20130189344A1
公开(公告)日：2013-07-25
申请号：US13355712
申请日：2012-01-23
申请人： Susan J. Drapeau , Guobao Wei
发明人： Susan J. Drapeau , Guobao Wei
IPC分类号： A61K38/39 , A61K9/50 , A61K9/70 , A61P19/08 , A61P21/02 , A61P19/02 , A61K9/14 , A61P29/00 , B82Y5/00
CPC分类号： A61K47/42 , A61K9/0024 , A61K9/06 , A61K31/573 , A61K38/00 , A61K38/1875 , A61K38/2066 , B82Y5/00 , C07K16/241 , C07K16/245
摘要： Human lubricating gels, methods and kits for delivering a therapeutic agent to a target tissue site beneath the skin of a patient utilizing human lubricating gel are provided, the human lubricating gel being capable of adhering to the target tissue site and comprising one or more biodegradable formulations containing an effective amount of the therapeutic agent. In various embodiments, the human lubricating gel is sprayable and hardens after contacting the target tissue site.
摘要翻译：提供人体润滑凝胶，用于使用人体润滑凝胶将治疗剂递送到患者皮肤下面的靶组织部位的方法和试剂盒，所述人润滑凝胶能够粘附到靶组织部位并且包含一种或多种可生物降解制剂含有有效量的治疗剂。在各种实施方案中，人体润滑凝胶在与靶组织部位接触后是可喷雾的和硬化的。

119. 发明申请

US20130165430A1 COMPOSITION AND METHOD FOR COMPOUNDED THERAPY 有权
标题翻译：用于复合治疗的组合物和方法
公开(公告)号：US20130165430A1
公开(公告)日：2013-06-27
申请号：US13564525
申请日：2012-08-01
申请人： Jay Richard Ray, II , Charles D. Hodge
发明人： Jay Richard Ray, II , Charles D. Hodge
IPC分类号： A61K31/5415 , A61P21/02 , A61P25/00 , A61P29/00 , A61P25/08
CPC分类号： A61K9/0014 , A61K9/06 , A61K31/167 , A61K31/53 , A61K31/5415 , A61K31/7048 , A61K2300/00 , A61K31/63
摘要： The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients. For instance, the transdermal cream may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, and/or other active ingredients. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels.
摘要翻译：本实施例涉及局部递送的复合药物。透皮霜可以同时提供多种药物的有效局部给药。透皮霜可以包括低浓度的局部麻醉剂，NSAID，抗惊厥药和/或其它活性成分。例如，透皮霜可以包括利多卡因，丙胺卡因，美洛昔康和拉莫三嗪和/或托吡酯。或者，透皮霜可以包括利多卡因/丙胺卡因基础霜，其中加入一种或多种地面药物的细粉末以形成复合药物。粉末形式的复合药物可以通过研磨NSAIDs，抗惊厥药，神经抑制剂，抗抑郁药，肌肉松弛剂，NMDA受体拮抗剂，阿片剂或阿片样物质激动剂和/或其它药剂来产生。粉末形式的复合药物可以包括美洛昔康，拉莫三嗪，托吡酯和/或其它活性成分。在另一方面，本实施方案涉及配制药物和透皮霜或凝胶的方法。

120. 发明申请

US20130165429A1 COMPOSITION AND METHOD FOR COMPOUNDED THERAPY 有权
标题翻译：用于复合治疗的组合物和方法
公开(公告)号：US20130165429A1
公开(公告)日：2013-06-27
申请号：US13448088
申请日：2012-04-16
申请人： Jay Richard Ray, II , Charles D. Hodge
发明人： Jay Richard Ray, II , Charles D. Hodge
IPC分类号： A61K31/5415 , A61P21/02 , A61P25/24 , A61P29/00 , A61P25/08
CPC分类号： A61K9/0014 , A61K9/06 , A61K31/167 , A61K31/53 , A61K31/5415 , A61K31/7048 , A61K2300/00 , A61K31/63
摘要： The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously; may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients; and may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, other active ingredients, and DMSO or Sterile Water for Irrigation. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels.
摘要翻译：本实施例涉及局部递送的复合药物。透皮霜可以同时提供多种药物的有效局部给药; 可以包括低浓度的局部麻醉剂，NSAID，抗惊厥药和/或其它活性成分; 并且可以包括利多卡因，丙胺卡因，美洛昔康和拉莫三嗪和/或托吡酯。或者，透皮霜可以包括利多卡因/丙胺卡因基础霜，其中加入一种或多种地面药物的细粉末以形成复合药物。粉末形式的复合药物可以通过研磨NSAIDs，抗惊厥药，神经抑制剂，抗抑郁药，肌肉松弛剂，NMDA受体拮抗剂，阿片剂或阿片样物质激动剂和/或其它药剂来产生。粉末形式的复合药物可以包括美洛昔康，拉莫三嗪，托吡酯，其他活性成分，和DMSO或无菌水用于灌溉。在另一方面，本实施方案涉及配制药物和透皮霜或凝胶的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式